High-dose, Short-term Steroid and Low-dose Long-term Steroid Use in ARDS Caused by COVID-19

Biruni University

Status: Unknown

Conditions: Short-term (3 Days) High-dose (1000 mg) Systemic Methylprednisolone

Treatments: Behavioral: systemic methylprednisolone

Study type: Observational

Funder types: Other

Identifiers

NCT05047874

BIRUNI 1

Details and patient eligibility

About

In this study, we aimed to compare, retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic methylprednisolone with those to whom low-dose long-term (2x 40 mg) systemic methylprednisolone was administered.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 105 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Between June 1, 2020 and February 1, 2021, hospitalized in the General intensive care unit of Biruni University Medical Faculty Hospital with the diagnosis of COVID 19;
• patients over 18 years of age; (for the diagnosis of COVID 19; Identification of SARS-CoV-2 by reverse transcription-polymerase chain reaction (RT-PCR) in nasopharyngeal swab or sputum samples and Abnormal lung computed tomography finding (CT) scan finding with <90% oxygen saturation at rest (bilateral, subpleural, peripheral ground glass opacities)

Exclusion criteria

• Patients with a diagnosis of steroid allergy or developing during treatment;
• pregnant or lactating women;
• Patients with active malignancy;
• Patients taking any immunosuppressive agent.

Trial design

200 participants in 2 patient groups

short-term (3 days) high-dose (1000 mg) systemic methylprednisolone

Description:

retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic methylprednisolone

Treatment:

Behavioral: systemic methylprednisolone

low-dose long-term (2x 40 mg) systemic methylprednisolone

Description:

retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom low-dose long-term (2x 40 mg) systemic methylprednisolone

Treatment:

Behavioral: systemic methylprednisolone